ArticleAnnals of internal medicine2022
In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
Gabriel M AisenbergPubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it